Polopyrine S (Polopiryna) 300mg x 30 tablets

Polopyrine S (Polopiryna) 300mg contains acetylsalicylic acid. It is an active substance with analgesic, antipyretic and anti-inflammatory effect. The drug is indicated for adults and adolescents over 16 years of age.

Composition Polopyrine S (Polopiryna) 300mg:

Active substance: acetylsalicylic acid. One tablet contains 300mg of acetylsalicylic acid and excipients: corn starch, powdered cellulose, microcrystalline cellulose.

Action Polopyrine S (Polopiryna) 300mg:

The active substance used in the medicinal product Polopiryna S 300mg is acetylsalicylic acid. It is an anti-inflammatory, analgesic and antipyretic drug. Indications for use of the drug are, among others mild to moderate pain, symptoms of colds and flu with fever, as well as rheumatoid arthritis.

Application of Polopyrine S (Polopiryna) 300mg:

The medicinal product Polopirin S 300mg indicated for use in the treatment of: pain of various origins of mild or moderate severity (including headache, toothache, muscle pain, joint pain); ailments that accompany colds and flu with fever; medical conditions that require long-term use of high-dose acetylsalicylic acid, including rheumatoid arthritis, and in the treatment of myocardial infarction and prophylaxis of recurrent myocardial infarction.

Additional information: The product should be stored out of reach of children at room temperature. It is recommended to protect against moisture and light. The possibility of using the drug in the first and second trimester of pregnancy should be consulted with a doctor. Do not drink alcohol during treatment.

Contraindications Polopyrine S (Polopiryna) 300mg:

Do not use in case of hypersensitivity to any component of the drug, as well as to other nonsteroidal anti-inflammatory drugs. Do not use in the case of bronchial asthma, chronic respiratory disease, hay fever or swelling of the nasal mucosa. Do not use in the case of active gastric and / or duodenal ulcer, inflammation or gastrointestinal bleeding (gastrointestinal bleeding or ulceration may occur), severe liver or kidney failure, severe heart failure; blood coagulation disorders (e.g. haemophilia, thrombocytopenia). Do not use simultaneously with anticoagulants (e.g. coumarin derivatives, heparin). Do not use in the case of glucose-6-phosphate dehydrogenase deficiency. Do not use concomitantly with methotrexate at doses of 15mg weekly or higher. Do not use in children and adolescents under 16 years of age (primarily in the course of viral infections, due to the risk of Reye's syndrome). Do not use during the third trimester of pregnancy and during breast-feeding.

Side effects:
Some people may experience side effects when taking this medicine. Side effects after using acetylsalicylic acid. Blood and lymphatic system disorders: thrombocytopenia, gastrointestinal micro-bleeding anemia, hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency, leukopenia, agranulocytosis, eosinopenia, increased risk of bleeding, prolonged bleeding time, prolonged prothrombin time. Immune system disorders: hypersensitivity reactions: rash, urticaria, angioedema, bronchospasm, shock. Nervous system disorders: tinnitus (usually a sign of overdose), hearing impairment, dizziness. Cardiac disorders: heart failure. Vascular disorders: hypertension. Gastrointestinal disorders: indigestion, heartburn epigastric fullness, nausea, vomiting, anorexia, abdominal pain, gastrointestinal bleeding, gastric mucosal damage, ulcer disease, perforation (gastric ulcer occurs in 15% of patients receiving acetylsalicylic acid for long periods). Hepato-biliary disorders: focal hepatocellular necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin . Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. anorexia, abdominal pain, gastrointestinal bleeding, damage to the gastric mucosa, ulceration, perforation (gastric ulcer occurs in 15% of patients on chronic acetylsalicylic acid treatment). Hepato-biliary disorders: focal hepatocellular necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin . Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. anorexia, abdominal pain, gastrointestinal bleeding, damage to the gastric mucosa, ulceration, perforation (gastric ulcer occurs in 15% of patients on chronic acetylsalicylic acid treatment). Hepato-biliary disorders: focal hepatocellular necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin . Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. activating a peptic ulcer, perforation (gastric ulcer occurs in 15% of patients on long-term intake of acetylsalicylic acid). Hepato-biliary disorders: focal hepatocellular necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin . Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. activating a peptic ulcer, perforation (gastric ulcer occurs in 15% of patients on long-term intake of acetylsalicylic acid). Hepato-biliary disorders: focal hepatocellular necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin . Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. focal hepatic necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin. Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis. focal hepatic necrosis, tenderness and enlargement of the liver (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or liver disease), transient increases in serum transaminases, alkaline phosphatase and bilirubin. Renal and urinary disorders: proteinuria, presence of leukocytes and erythrocytes in urine, renal papillary necrosis, interstitial nephritis.

Dosage of Polopyrine S (Polopiryna) 300mg tablets:

Use as directed by your doctor or the instructions on the leaflet. Use orally, take during or after a meal, drink plenty of water. If you have trouble swallowing, you can first dissolve half a glass of water or milk. For pain and fever usually used - adults: 1-2 tablets (300-600mg acetylsalicylic acid) every 4 hours. Maximum daily dose: 3g acetylsalicylic acid. Adolescents over 16 years of age: 2-3 tablets daily (600-900mg acetylsalicylic acid). In inflammation, it is recommended to use after consulting a doctor, usually used: in rheumatic fever: 3 tablets (900mg of acetylsalicylic acid) 4 times a day; in rheumatoid arthritis: 2 tablets (600mg acetylsalicylic acid) 3-4 times a day. Myocardial infarction, prevention of myocardial infarction: 1 / 2-1 tablets (150-300mg acetylsalicylic acid) daily. Duration of symptomatic treatment: without consultation, it can be used for a maximum of 3 days. The lowest effective doses are recommended.